Remicade Biosimilar Market Size & Share and Forecast 2017-2025: Development Trends and Future Growth

Marketresearchreports.biz has announced the addition of a new research study on the "Remicade Biosimilar Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its report database.

The main objective of this report is to define, describe, and forecast the global “Remicade Biosimilar” market on the basis of types of applications, major sectors, deployment models, organization size, and regions. The report contains an analysis of the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges). It aims to strategically analyze the micromarkets with respect to individual growth trends, prospects, and their contribution to the market. The report attempts to forecast the market size for 5 major regions, namely, North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. It contains key vendor profiles and comprehensively analyzes their core competencies. The report also tracks and analyzes competitive developments, including partnerships, collaborations, acquisitions, new product developments, and R&D activities in the market.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1510063

Demand for biological products is high for the treatment of a large number of diseases. However, demand for biosimilar products is increasing to lower health care costs. Biosimilar products are derived in reference to biological products and have similar safety, efficacy, purity, and effectiveness when compared to the original products. Biosimilar can be characterized as a sort of biologic item that is profoundly like an as of now FDA approved biologic drug, known as reference drug. Biosimilars are drugs approved by the U.S. FDA and the European Medicine Agency (EMA) and show no clinical and meaningful difference from the reference biological product. These biosimilar products can be approved only for indications which are previously approved for the reference biological product by authorized regulatory bodies.

In 1998, the U.S. FDA licensed Remicade (infliximab), a monoclonal antibody originally produced by Janssen Biotech, Inc. and Merck & Co. in partnership. Its primary indication included Crohn’s disease in both adult and pediatric patients. It is also indicated for the treatment of ulcerative colitis, spinal psoriatic arthritis, plague psoriasis, and rheumatic arthritis when given in combination with methotrexate. The U.S. FDA approved biosimilar to Remicade named Inflectra on April 05, 2016. Pfizer launched Inflectra in the market at 15% discount on the original market price of the reference product. However, in April 2017, another biosimilar Renflexis (infliximab-abda), a tumor necrosis factor to Remicade by Samsung Bioepis and Merck & Co., was approved to be launched into the market. It is approved for almost all the indications that were approved under Remicade such as ulcerative colitis, spinal psoriatic arthritis, plague psoriasis, rheumatic arthritis, and ankylosing spondylitis.

Increase in incidence of autoimmune disorders such as rheumatoid arthritis, and psoriasis, patent expiry of branded drugs, and rise in health care costs drive the Remicade biosimilar market. Additionally, faster entry of Biosimilars into the Europe market leads to cost reduction and faster medicines accessibility help to grow this market. However, serious side effects associated with the drug could lead to fatality. This factor restraints the market.

View Full Report @ https://www.marketresearchreports.biz/reports/1510063/remicade-biosimilar-global-industry-market-research-reports

The global Remicade biosimilar market can be segmented based on approved indication and region. In terms of approved indication, the market can be categorized into ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ankylosing spondylitis. Ulcerative colitis and rheumatoid arthritis show higher demand due to increase in number of cases of these diseases. Psoriasis also increase market demand owing to increase in the cases of autoimmune diseases. Based on region, the global Remicade biosimilar market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the market owing to high incidence of autoimmune diseases and increase in geriatric population. Europe is the second largest market for Remicade. Easy access to biosimilar medications in the region drives the market. India, southeast Asia, and China are emerging markets for biosimilar medicines because of changing lifestyle and increase in healthcare facilities in these regions.

Key players in the global Remicade biosimilar market comprise Alvogen, Napp Pharmaceuticals, Janssen Biotech, Inc., Merck &Co., Pfizer, Inc., Cell Trion, and Nippon Kayaku.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis

Request For Enquiry @ https://www.marketresearchreports.biz/sample/enquiry/1510063

The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market

About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact us

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.